AAAAAA
Results: 26-50/77
Authors:
TOLLEFSON GD
TRAN PV
HAMILTON S
KUNTZ A
Citation: Gd. Tollefson et al., OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF PSYCHOSIS - PRELIMINARY-REPORT, Schizophrenia research, 24(1-2), 1997, pp. 191-192
Authors:
TOLLEFSON GD
TRAN PV
BIRKETT M
SHOSHANI D
Citation: Gd. Tollefson et al., TREATMENT FAILURE WITH CLOZAPINE - CAN OLANZAPINE BE THE ALTERNATIVE THERAPY, Schizophrenia research, 24(1-2), 1997, pp. 191-191
Authors:
TOLLEFSON GD
SANGER TM
BEASLEY CM
Citation: Gd. Tollefson et al., THE COURSE OF PRIMARY AND SECONDARY NEGATIVE SYMPTOMS IN A CONTROLLEDTRIAL WITH OLANZAPINE, Schizophrenia research, 24(1-2), 1997, pp. 192-192
Authors:
TOLLEFSON GD
LU YL
SANGER TM
BEASLEY CM
TRAN PV
Citation: Gd. Tollefson et al., OLANZAPINE IN THE TREATMENT OF SCHIZOAFFECTIVE DISORDER, Schizophrenia research, 24(1-2), 1997, pp. 192-193
Authors:
TOLLEFSON GD
LU YL
Citation: Gd. Tollefson et Yl. Lu, COMORBID MOOD DISTURBANCE IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 192-192
Authors:
TOLLEFSON GD
SANGER TM
LIEBERMAN JA
Citation: Gd. Tollefson et al., OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF FIRST EPISODE PSYCHOSIS, Schizophrenia research, 24(1-2), 1997, pp. 193-193
Authors:
TRAN PV
HAMILTON SH
KUNTZ AJ
POTVIN JH
ANDERSEN SW
BEASLEY C
TOLLEFSON GD
Citation: Pv. Tran et al., DOUBLE-BLIND COMPARISON OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS, Journal of clinical psychopharmacology, 17(5), 1997, pp. 407-418
Authors:
TRAN PV
DELLVA MA
TOLLEFSON GD
BEASLEY CM
POTVIN JH
KIESLER GM
Citation: Pv. Tran et al., EXTRAPYRAMIDAL SYMPTOMS AND TOLERABILITY OF OLANZAPINE VERSUS HALOPERIDOL IN THE ACUTE TREATMENT OF SCHIZOPHRENIA, The Journal of clinical psychiatry, 58(5), 1997, pp. 205-211
Authors:
BEASLEY CM
TOLLEFSON GD
TRAN PV
Citation: Cm. Beasley et al., EFFICACY OF OLANZAPINE - AN OVERVIEW OF PIVOTAL CLINICAL-TRIALS, The Journal of clinical psychiatry, 58, 1997, pp. 7-12
Authors:
BEASLEY CM
TOLLEFSON GD
TRAN PV
Citation: Cm. Beasley et al., SAFETY OF OLANZAPINE, The Journal of clinical psychiatry, 58, 1997, pp. 13-17
Authors:
TOLLEFSON GD
Citation: Gd. Tollefson, CONCLUDING REMARKS, The Journal of clinical psychiatry, 58, 1997, pp. 73-73
Authors:
TOLLEFSON GD
TRAN PV
HAMILTON S
KUNTZ A
Citation: Gd. Tollefson et al., OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF PSYCHOSIS - PRELIMINARY-REPORT, Biological psychiatry, 41, 1997, pp. 66-66
Authors:
TOLLEFSON GD
STREET J
TAMURA R
SANGER TM
Citation: Gd. Tollefson et al., DYSKINETIC SYMPTOMS - OLANZAPINE VERSUS HALOPERIDOL, Biological psychiatry, 41, 1997, pp. 67-67
Authors:
TOLLEFSON GD
SANGER TD
LIEBERMAN JA
Citation: Gd. Tollefson et al., OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF FIRST EPISODE PSYCHOSIS, Biological psychiatry, 41, 1997, pp. 248-248
Authors:
TOLLEFSON GD
SAYLER ME
BLOMGREN SL
Citation: Gd. Tollefson et al., THE COURSE OF PSYCHOMOTOR AGITATION DURING PHARMACOTHERAPY OF DEPRESSION - ANALYSIS FROM DOUBLE-BLIND, CONTROLLED TRIALS, Biological psychiatry, 41, 1997, pp. 334-334
Authors:
TOLLEFSON GD
LU Y
Citation: Gd. Tollefson et Y. Lu, COMORBID MOOD DISTURBANCE IN SCHIZOPHRENIA, Biological psychiatry, 41, 1997, pp. 349-349
Authors:
BODICK NC
OFFEN WW
LEVEY AI
CUTLER NR
GAUTHIER SG
SATLIN A
SHANNON HE
TOLLEFSON GD
RASMUSSEN K
BYMASTER FP
HURLEY DJ
POTTER WZ
PAUL SM
Citation: Nc. Bodick et al., EFFECTS OF XANOMELINE, A SELECTIVE MUSCARINIC RECEPTOR AGONIST, ON COGNITIVE FUNCTION AND BEHAVIORAL SYMPTOMS IN ALZHEIMER-DISEASE, Archives of neurology, 54(4), 1997, pp. 465-473
Authors:
TOLLEFSON GD
BEASLEY CM
TAMURA RN
TRAN PV
POTVIN JH
Citation: Gd. Tollefson et al., BLIND, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT-EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL, The American journal of psychiatry, 154(9), 1997, pp. 1248-1254
Authors:
TOLLEFSON GD
BEASLEY CM
TRAN PV
STREET JS
KRUEGER JA
TAMURA RN
GRAFFEO KA
THIEME ME
Citation: Gd. Tollefson et al., OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE AND SCHIZOPHRENIFORM DISORDERS - RESULTS OF AN INTERNATIONAL COLLABORATIVE TRIAL, The American journal of psychiatry, 154(4), 1997, pp. 457-465
Authors:
TOLLEFSON GD
SANGER TM
Citation: Gd. Tollefson et Tm. Sanger, NEGATIVE SYMPTOMS - A PATH ANALYTIC APPROACH TO A DOUBLE-BLIND, PLACEBO-CONTROLLED AND HALOPERIDOL-CONTROLLED CLINICAL-TRIAL WITH OLANZAPINE, The American journal of psychiatry, 154(4), 1997, pp. 466-474
Authors:
TOLLEFSON GD
BEASLEY CM
TRAN PV
TAMURA RN
SANGER TM
WOOD A
BEUZEN JN
Citation: Gd. Tollefson et al., OLANZAPINE VERSUS HALOPERIDOL - RESULTS OF THE MULTICENTER INTERNATIONAL TRIAL, Schizophrenia research, 18(2-3), 1996, pp. 3-3
Authors:
TOLLEFSON GD
HEILIGENSTEIN JH
TOLLEFSON SL
BIRKETT MA
KNIGHT DL
NEMEROFF CB
Citation: Gd. Tollefson et al., IS THERE A RELATIONSHIP BETWEEN BASE-LINE AND TREATMENT-ASSOCIATED CHANGES IN [H-3]-IMI PLATELET BINDING AND CLINICAL-RESPONSE IN MAJOR DEPRESSION, Neuropsychopharmacology, 14(1), 1996, pp. 47-53
Authors:
TOLLEFSON GD
Citation: Gd. Tollefson, COGNITIVE FUNCTION IN SCHIZOPHRENIC-PATIENTS, The Journal of clinical psychiatry, 57, 1996, pp. 31-39
Authors:
SMALL GW
BIRKETT M
MEYERS BS
KORAN LM
BYSTRITSKY A
NEMEROFF CB
ABUZZAHAB FS
ALEXOPOULOS GS
BIELSKI RJ
BORISON RL
BROD MS
COHENCOLE SA
COHN CK
DOWNS JM
DUPONT RL
FERGUSON JM
FOLKS DG
GOTTLIEB GL
GRABER B
MENOLASCINO FJ
HALARIS AE
HARTFORD JT
HERTZMAN M
JEFFERSON JW
JESTE DV
LAZARUS LW
NAKRA BR
OXENKRUG GF
RAPPAPORT SA
ROSENTHAL MH
SALZMAN C
SHRIVASTAVA RK
STOKES PE
WINSTON JL
WHEADON DW
SCHATZ EJ
MARVEL DE
ALBRITTON R
TOLLEFSON GD
LILLY E
Citation: Gw. Small et al., IMPACT OF PHYSICAL ILLNESS ON QUALITY-OF-LIFE AND ANTIDEPRESSANT RESPONSE IN GERIATRIC MAJOR DEPRESSION, Journal of the American Geriatrics Society, 44(10), 1996, pp. 1220-1225
Authors:
GOLDSTEIN DJ
RAMPEY AH
ROBACK PJ
WILSON MG
HAMILTON SH
SAYLER ME
TOLLEFSON GD
Citation: Dj. Goldstein et al., EFFICACY AND SAFETY OF LONG-TERM FLUOXETINE TREATMENT OF OBESITY - MAXIMIZING SUCCESS, Obesity research, 3, 1995, pp. 481-490